Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs have been updated June 1, 2023:
Effective July 1, 2023:
- Healthcare Administered Multiple Sclerosis
- Antifungals (formerly Antifungal Agents [Brexafemme/Cresemba/Noxafil/Vfend/Vivjoa])
- Parathyroid Hormone Analog Osteoporosis
- Rituximab
- Tezspire
- Urea Cycle Disorders
- Biologic Immunomodulators
- Vijoice
- Fintepla
- Continuous Glucose Monitoring Systems (CGM)
- Acute Migraine Agents
- CGRP
- HCPA CGRP
- Enjaymo
The following policies are archiving due to being retired:
Effective May 1, 2023:
- Gabapentin ER
Effective June 1, 2023:
- Lucemyra
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.